ExonHit seeks financing or partner to further EHT 0202 development in Alzheimer's
This article was originally published in Scrip
Executive Summary
ExonHit Therapeutics is looking for financing or a partner to progress development of its lead candidate for Alzheimer's disease, EHT 0202, into Phase IIb.